Simultaneous detection of different serum pepsinogens and its primary application

Table 1 Precision of dual-label assay for PG I and PG II in serum of controls¹

	PG I (μg/L)		PG II (μg/L)
	mean ± SD	CV (%)	mean ± SD	CV (%)
Serum pool 1
Within-run (n = 10)	43.2 ± 1.36	3.2	5.23 ± 4.62	4.8
Between-run (n = 6)	42.8 ± 2.28	5.1	5.65 ± 6.45	6.7
Serum pool 2
Within-run (n = 10)	105.0 ± 1.88	2.3	11.7 ± 3.66	3.9
Between-run (n = 6)	103.8 ± 2.73	3.6	10.5 ± 4.55	5.1
Serum pool 3
Within-run (n = 10)	198.2 ± 5.31	6.3	22.0 ± 3.88	4.6
Between-run (n = 6)	186.7 ± 4.35	5.4	21.2 ± 5.71	8.3

¹Served as controls. PG: Pepsinogen; CV: Coefficient of variation.

Table 2 Serum PG level and PG I/PG II ratio in healthy controls and patients with duodenal ulcer, gastric ulcer, atrophic gastritis, superficial gastritis and gastric cancer (mean ± SD)

Diagnosis	n	Age (yr)	PG I (μg/L)	PG II (μg/L)	PG I/PG II ratio
Healthy controls	500	41.5 ± 18.8	150.3 ± 45.1	10.4 ± 8.4	14.5 ± 4.3
Patients with duodenal ulcer	112	43 ± 14.2	252.9 ± 84.5d	18.4 ± 16.0d	13.7 ± 8.0
Patients with gastric ulcer	44	37 ± 11.2	221.2 ± 91.7d	15.6 ± 12.4b	14.2 ± 7.1
Patients with atrophic gastritis	21	48 ± 9.7	89.5 ± 51.2d	12.9 ± 9.39	6.9 ± 6.2b
Patients with superficial gastritis	76	35 ± 7.4	175.3 ± 45.8a	12.7 ± 10.1	13.8 ± 5.3
Patients with gastric cancer	126	55 ± 12.2	157.1 ± 81.9	15.6 ± 14.4b	13.4 ± 7.8

^aP < 0.05,

^bP < 0.01,

^dP < 0.001 vs healthy controls.

Table 3 PG I and PG II values and PG I/PG II ratio in patients with gastric carcinoma and duodenal ulcer n (%)

	n	PG I (μg/L)			PG II (μg/L)		PG I/PG II ratio
		< 60	60-240	> 240	≤ 27	> 27	≤ 6	> 6
Patients with gastric cancer	126	17 (13.5)	88 (69.8)	21 (16.7)	109 (86.5)	17 (13.5)	25 (19.8)	101 (80.2)
Patients with duodenal ulcer	112	0	69 (61.6)	43 (38.4)	100 (89.2)	12 (10.8)	3 (2.7)	109 (97.3)